

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-93. (Cancelled)

94. (New) An isolated polynucleotide selected from the group consisting of:

- a. a polynucleotide sequence of SEQ ID NO:1;
- b. a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1; and
- c. a polynucleotide sequence complementary to either a) or b).

95. (New) An isolated polynucleotide selected from the group consisting of:

- a. a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 2-7;
- b. a naturally-occurring polynucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 2-7; and
- c. a polynucleotide sequence complementary to either a) or b).

96. (New) An isolated polypeptide sequence comprising an amino acid sequence selected from the group consisting of:

- a. an amino acid sequence as set forth in any of SEQ ID NOS. 8, 28-37;
- b. a naturally-occurring amino acid sequence having at least 90% sequence identity to any of the amino acid sequence of SEQ ID NOS. 8, 28-37;
- c. a biologically active fragment of any of the amino acid sequence of SEQ ID NOS. 8, 28-37; and
- d. an immunogenic fragment of the amino acid sequence of SEQ ID NOS. 8, 28-37.

97. (New) An isolated polypeptide fragment capable of generating an immune response against the SARS virus selected from the group consisting of
- a. a polypeptide sequence selected from the group consisting of SEQ ID NOs: 9-14;
 - b. a naturally-occurring polypeptide sequence having at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 9-14.
98. (New) A vaccine effective against a human SARS virus infection comprising a peptide having a sequence selected from the group consisting of SEQ ID NOs: 1-7 and a pharmaceutically acceptable carrier.
99. (New) A vaccine effective against a human SARS virus infection comprising a peptide having a sequence selected from the group consisting of SEQ ID NOs: 8-14, 28-37 and a pharmaceutically acceptable carrier.
100. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:
- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and
 - b. at least one polypeptide fragment selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.
101. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:
- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and
 - b. two polypeptide fragments selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.
102. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:
- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and

- b. three polypeptide fragments selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.
103. (New) A recombinant adenovirus expressing SARS viral proteins, comprising:
- a. an adenovirus, wherein portions of its sequence responsible for replication having been deleted, thus rendering the adenovirus incapable of replicating itself; and
 - b. a plurality of polypeptide fragments selected from the group consisting of the spike protein, the small membrane protein, the small envelope protein, and the nuclear capsid protein.
104. (New) A SARS vaccine comprising of the recombinant adenovirus of claim 100, and a pharmaceutically acceptable carrier.
105. (New) A method of modulating the immune response to human SARS virus infection, comprising administering an effective amount of the vaccine according to claim 104.
106. (New) A method of immunizing a subject against a SARS virus infection comprising administering to said subject the vaccine of claim 104.
107. (New) The method of claim 106, wherein said subject is a human.